Loading
Guerbet Stock: price and insider trades · France
1 insider bought €80k of shares over the last 90 days, the latest by Vincent DAGOMMER, filed 06 Aug 2026.
Guerbet: what insiders have been doing
Guerbet, founded in 1926, is a Healthcare & Pharma company based in Villepinte, France. Its directors and officers file their transactions with AMF. Between 22 October 2025 and 22 October 2026, 2 insiders published 4 filings.
Only purchases show up on the open market, 4 purchases in all worth €96k, filed by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 2 board members. One trade stands out by size: a purchase of €40k from Vincent DAGOMMER, disclosed on 6 August 2026, or 0.055% of market capitalisation.
The latest purchase dates back some time: it was published 78 days ago, on 6 August 2026. Filings reach the AMF feed a median of 2 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade.
Compared with its exchange (314 companies, median 7 filings), a count of 4 filings is below the norm. Since 2022, the database holds 20 purchases and 6 sales by insiders of the company.
This summary is built from AMF disclosures alone and does not predict where the share price will go.
Insider Decl.
26
Thresholds
n/a
Buy Volume
€407,893
20 ops. · all time
Sell Volume
€218,181
6 ops. · all time
Who traded when
BuySaleMarc Massiot4 buys
Mark Fouquet3 sales
Vincent DAGOMMER3 buys
Carine DAGOMMER1 buy
Michèle Lesieur1 buy
Since the insiders bought
- -27.9%Entry €8.27 · Close 19 Oct 2026 €5.96
- -63.4%Entry €16.28 · Close 19 Oct 2026 €5.96
- -57.1%Entry €13.90 · Close 19 Oct 2026 €5.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 16,212 of 26,284 companies
44.2
score / 100
Value58
Quality30
FCF yld61%
Earn yld-149%
EV/EBITDA7.1x
ROE-48%
Gross mgn71%
Net mgn-14%
Debt/EBITDA6.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€5.81
Analyst consensus
3 analysts3.67/5
€8.00Target €8.43(+45%)€9.00
Income statement
Revenue€798.7M
Gross profit€566.2M71% margin
EBITDA€72.6M9% margin
Net income-€108.3M-17.8% margin
Valuation
PER (forward)4.7x
P/Book0.3x
Beta1.07
Balance sheet & cash
Market cap€72.9M
Total debt€441.2M
Free Cash Flow€44.5M
Debt / Equity208%
Profitability & ownership
ROE-48.4%
ROA-1.6%
% insiders63.2%
% institutions4.4%
Last declaration on 6 August 2026
Declarations26 total
3,788 shares@ €7.93070.034% mcap100.0% of flowActionEuronext ParisISIN FR00000325262026DD1132400
Canonical exit: 2 Nov 2026 (T+90)
5,027 shares@ €7.94840.055% mcap50.2% of flowActionEuronext ParisISIN FR00000325262026DD1132400-T2
Canonical exit: 3 Nov 2026 (T+90)
1,185 shares@ €8.04880.013% mcap12.0% of flowActionEuronext ParisISIN FR00000325262026DD1132400-T3
Canonical exit: 4 Nov 2026 (T+90)
1,100 shares@ €15.00100.0% of flowActionEuronext ParisISIN FR00000325262025DD1068653
Canonical exit: 1 Feb 2026 (T+90)
200 shares@ €13.68100.0% of flowActionEuronext ParisISIN FR00000325262025DD1061629
Canonical exit: 1 Jan 2026 (T+90)
3,062 shares@ €17.999427.3% of flowActionEuronext ParisISIN FR00000325262025DD1030977
Canonical exit: 6 Jul 2025 (T+90)
1,000 shares@ €19.1735.8% of flowActionEuronext ParisISIN FR00000325262025DD1030456
Canonical exit: 2 Jul 2025 (T+90)
1,475 shares@ €26.821219.6% of flowActionEuronext ParisISIN FR00000325262025DD1022055
Canonical exit: 25 May 2025 (T+90)
2,242 shares@ €26.877729.8% of flowActionEuronext ParisISIN FR00000325262025DD1022050
Canonical exit: 22 May 2025 (T+90)
2,200 shares@ €26.0173.1% of flowActionEuronext ParisISIN FR00000325262024DD1008605
800 shares@ €26.2826.9% of flowActionEuronext ParisISIN FR00000325262024DD1008606
3,000 shares@ €25.989366.2% of flowActionEuronext ParisISIN FR00000325262024DD1008567
142 shares@ €35.1369.3% of flowActionEuronext ParisISIN FR00000325262024DD992115
Canonical exit: 17 Nov 2024 (T+90)
300 shares@ €34.337519.3% of flowActionEuronext ParisISIN FR00000325262024DD991827
Canonical exit: 13 Nov 2024 (T+90)
1,000 shares@ €34.3564.2% of flowActionEuronext ParisISIN FR00000325262024DD991729
Canonical exit: 10 Nov 2024 (T+90)
550 shares@ €32.1815.0% of flowActionEuronext ParisISIN FR00000325262024DD961339
1,200 shares@ €18.445100.0% of flowActionEuronext ParisISIN FR00000325262024DD957060
1,200 shares@ €18.44518.8% of flowActionEuronext ParisISIN FR00000325262024DD957770
722 shares@ €18.13976.5% of flowActionEuronext ParisISIN FR00000325262023DD936500
Canonical exit: 1 Feb 2024 (T+90)
2,000 shares@ €17.0416.9% of flowActionEuronext ParisISIN FR00000325262023DD936320
Canonical exit: 28 Jan 2024 (T+90)
1,000 shares@ €16.8031.4% of flowActionEuronext ParisISIN FR00000325262023DD935443
Canonical exit: 23 Jan 2024 (T+90)
1,000 shares@ €16.460930.8% of flowActionEuronext ParisISIN FR00000325262023DD934603
Canonical exit: 22 Jan 2024 (T+90)
300 shares@ €16.469.2% of flowActionEuronext ParisISIN FR00000325262023DD928061
Canonical exit: 2 Aug 2023 (T+90)
1,834 shares0ActionHors plateforme de négociationISIN FR00000325262022DD850219
Canonical exit: 29 Sept 2022 (T+90)
167 shares0ActionHors plateforme de négociationISIN FR00000325262022DD850226
Canonical exit: 29 Sept 2022 (T+90)
25 of 26 declarations
About Guerbet
Guerbet is a French healthcare group and a recognized global specialist in medical imaging. The company focuses on contrast media, delivery systems, selected medical devices, and digital and AI-enabled solutions for diagnostic imaging and interventional radiology. Its roots go back to 1926, when the André Guerbet laboratory was founded, building on the legacy of Marcel Guerbet and the historical Lipiodol® product, which remains closely linked to the company’s heritage.
Guerbet’s business model is centered on products that improve the quality, precision, and safety of imaging procedures. Its portfolio spans diagnostic imaging, including contrast agents for X-ray, MRI, ultrasound, and nuclear medicine, as well as interventional radiology, where its solutions help physicians visualize vessels and tissues and support minimally invasive procedures. The group is also moving further into digital healthcare, particularly through AI-based tools designed to make diagnosis faster and more accurate and to support clinical decision-making.
Read moreShow less
The company has a broad international footprint, marketing its products in more than 114 countries and operating directly in more than 20 countries across Europe, Asia, Oceania, North America, and Latin America. At the end of 2025, Guerbet employed 2,746 people worldwide. Its innovation platform is supported by research and development centers in France, the United States, and Israel, and the group invests around 9% of sales in R&D, underscoring the science-intensive nature of the business.
From a market perspective, Guerbet occupies a specialized position in a highly regulated and technically demanding industry. Demand is supported by the increasing use of imaging in oncology, neurology, vascular care, and other disciplines, while the company benefits from significant barriers to entry linked to product safety, regulatory approval, and clinical adoption. In 2024, Guerbet generated revenue of €841.1 million, up 9.0% at constant exchange rates and like-for-like, and materially improved profitability, highlighting the resilience of its core business and the contribution of product mix optimization, pricing discipline, and geographic diversification.
